[Table/Fig-2]:

The distribution of serum, voided urine and renal pelvic urine‡ CA19-9 levels in patients being operated for giant hydronephrosis (group 1) and control (group 2)

	Mean ± SD Serum CA19-9 (U / ml)	Mean ± SD Voided Urine CA19-9 (U / ml)	Mean ± SD Renal pelvic urine CA19-9‡ (U / ml)
Giant Hydronephrosis patients (Group 1)
Nephrectomy (1 A) Preoperative Post-operative at 3 months Post-operative at 9 months	2113.52 ± 613.94 10.84 ± 2.03* 10.56 ± 1.2*	11003.34 ± 4274.38 22.67 ± 3.03* 21.50 ± 2.89*	59336.02 ± 24928.36 _ _
Pyeloplasty (1 B) Preoperative Postoperative at 3 months Postoperative at 9 months	1425.58 ± 705.13 18.42 ± 4.6* 11.12 ± 1.50*	5280.45 ± 1809.05 71.30 ± 37.75* 21.45 ± 1.88*	36169.03 ± 26238.85 _ _
Ureterocalicostomy (1 C) Preoperative Postoperative at 3 months Postoperative at 9 months	2007.87 ± 323.50 20.36 ± 6.77* 10.41 ± 1.31*	6024.0750 ± 1600.77 87.68 ± 66.24* 21.22 ± 1.35*	66325.10 ± 31334.36 _ _
Healthy Controls (Group 2)	10.39 ± 1.96	21.69 ± 1.40	_

*p< .05 Preoperative values as compared to postoperative values.

‡ Only in group 1.

CA: Carbohydrate antigen, SD: Standard deviation.